secwatch.observer — SEC 8-K summary
======================================

Issuer:     CapForce Inc. (CFOR)
CIK:        0001293818
Form:       8-K
Filed at:   2023-03-30T23:59:59+00:00
Accession:  0001079973-23-000394
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

OpGen reports FY2022 revenue $2.6M, down 40% YoY; guides FY2023 revenue $4-5M
-----------------------------------------------------------------------------

- FY2022 total revenue ~$2.6M vs $4.3M in 2021; Q4 revenue $722K, down 48% YoY but up 61% QoQ.
- Operating expenses $37.2M for FY2022, including $12.3M goodwill and IPR&D impairment charges.
- Cash and equivalents $7.4M at Dec 31, 2022, down from $36.1M; recent $7.5M public offering closed.
- FY2023 guidance: revenue $4-5M; net cash consumption $4.5-5M per quarter; EIB loan restructuring discussions for EUR 3M due June 2023.
- Unyvero UTI FDA De Novo submission expected early Q2 2023; ARESiss first US commercial orders received.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1293818/000107997323000394/0001079973-23-000394-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1293818/000107997323000394/opgen_8k.htm
  HTML page:      https://secwatch.observer/filing/0001079973-23-000394

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer